{"gene":"ARID5B","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2011,"finding":"ARID5B forms a histone demethylase complex with PHF2. PHF2 is enzymatically inactive alone but becomes an active H3K9Me2 demethylase upon PKA-mediated phosphorylation; phosphorylated PHF2 then associates with ARID5B (a DNA-binding protein), and ARID5B itself is demethylated. The PHF2-ARID5B complex is then targeted to promoters where it removes the repressive H3K9Me2 mark to activate transcription.","method":"Co-immunoprecipitation, in vitro demethylase assays, ChIP, PKA phosphorylation assays, mutagenesis","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods including in vitro enzymatic assays, Co-IP, ChIP, and mutagenesis; replicated in subsequent papers","pmids":["21532585"],"is_preprint":false},{"year":2013,"finding":"ARID5B physically associates with the transcription factor Sox9 and recruits the histone demethylase PHF2 to the promoter regions of Sox9 target genes, stimulating H3K9me2 demethylation and thereby promoting chondrocyte differentiation. Arid5b-/- mice show retarded growth and delayed endochondral ossification, and H3K9me2 levels are increased at chondrogenic marker gene promoters in Arid5b-deficient chondrocytes.","method":"Co-immunoprecipitation (physical association with Sox9), ChIP (H3K9me2 levels at promoters), Arid5b-/- mouse phenotyping, PHF2 knockdown rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, KO mouse with defined phenotype, and PHF2 knockdown rescue; multiple orthogonal methods in one study","pmids":["24276541"],"is_preprint":false},{"year":1999,"finding":"The ARID (MRF2/ARID5B) DNA-binding domain recognizes the core sequence AATA(C/T) through contacts in both major and minor grooves. Major groove contacts at positions 2, 3, and 4 of the core sequence are required for high-affinity binding, while positions 1 and 5 are contacted through the minor groove. The core sequence alone is not sufficient for high-affinity binding.","method":"Binding interference assays, binding site selection assays, kinetic analyses with synthetic oligonucleotides containing single base analogues","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple biochemical assays (interference, selection, kinetics with base analogues) establishing DNA recognition mechanism in one rigorous study","pmids":["10329386"],"is_preprint":false},{"year":2001,"finding":"NMR backbone dynamics of the MRF2/ARID5B ARID domain show that two flexible interhelical loops (and the C-terminal tail) are involved in DNA recognition. Upon DNA binding, flexible loops show reduced mobility while some well-structured regions (including the putative DNA-contacting helix) show decreased order parameters, indicating that protein dynamics are integral to DNA binding.","method":"15N NMR relaxation measurements, model-free analysis, chemical shift perturbation mapping","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural and dynamics study with functional validation via chemical shift perturbation; single lab but rigorous structural method","pmids":["11478881"],"is_preprint":false},{"year":2007,"finding":"The three-dimensional structure of the MRF2/ARID5B ARID domain in complex with target DNA was determined by NMR using paramagnetic spin-label distance constraints. MRF2 contacts DNA mainly through two flexible loops (L1 and L2): L1 contacts the phosphate backbone, while L2 and residues in adjacent helices interact with AT base pairs in the major groove.","method":"NMR spectroscopy with paramagnetic spin labeling, docking calculations","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure determination with spin-label distance constraints; single lab but rigorous structural methodology","pmids":["17407261"],"is_preprint":false},{"year":2003,"finding":"Targeted disruption of Mrf2/Arid5b in mice results in high neonatal mortality, severely reduced lipid accumulation in brown adipose tissue in neonates, and lean adult phenotype with significant reductions in brown and white adipose tissues. Mrf2-/- mice are resistant to high-fat diet-induced obesity, demonstrating that ARID5B is essential for lipid accumulation in postnatal life.","method":"Mrf2-/- knockout mouse generation and phenotyping (body composition, adipose tissue histology, high-fat diet challenge)","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with multiple defined phenotypic readouts (adipose tissue weight, lipid accumulation, body fat percentage, dietary challenge); replicated by subsequent conditional KO studies","pmids":["14651970"],"is_preprint":false},{"year":2018,"finding":"A short isoform of ARID5B is selectively induced through DNA hypomethylation in adaptive (cytomegalovirus-expanded) NK cells. Knockdown and overexpression studies demonstrated that ARID5B directly promotes mitochondrial membrane potential, expression of genes encoding electron transport chain components, oxidative metabolism, survival, and IFN-γ production in these cells.","method":"ARID5B knockdown (siRNA) and overexpression in human NK cells; measurement of mitochondrial membrane potential, oxygen consumption rate, and IFN-γ production; bisulfite sequencing for DNA methylation","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with multiple metabolic readouts, DNA methylation mapping, single lab but multiple orthogonal methods","pmids":["30061358"],"is_preprint":false},{"year":2018,"finding":"ARID5B is a direct transcriptional target of the TAL1 oncogenic complex in T-ALL and functions as a collaborating oncogenic factor. ARID5B co-occupies target genes with TAL1 and coordinately controls their expression. ARID5B positively regulates expression of TAL1 and its regulatory partners, and activates MYC expression. Forced expression of ARID5B in immature thymocytes causes thymus retention, differentiation arrest, radioresistance, and tumor formation in zebrafish.","method":"ChIP-seq (ARID5B and TAL1 co-occupancy), knockdown/overexpression studies, ARID5B forced expression in zebrafish thymocytes, superenhancer analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP-seq for co-occupancy, KD and OE with defined phenotypes, in vivo zebrafish tumor model; multiple orthogonal methods","pmids":["29326336"],"is_preprint":false},{"year":2018,"finding":"ARID5B physically interacts with PHF2 in acute lymphoblastic leukemia cells. Ikaros directly regulates ARID5B expression, and restoring Ikaros function via Casein Kinase II inhibition promotes ARID5B expression through recruitment of H3K4me3 at the ARID5B promoter.","method":"Co-immunoprecipitation (ARID5B-PHF2 interaction), CK2 inhibition with CK2i, ChIP (H3K4me3 at ARID5B promoter), gene expression analysis","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP for interaction, ChIP for epigenetic regulation, CK2 inhibitor experiment; single lab with two orthogonal methods","pmids":["30420689"],"is_preprint":false},{"year":2018,"finding":"Arid5b-/- primary skeletal muscle cells exhibit differentiation defects and impaired sarcomeric assembly. Mechanistically, Arid5b-/- cells show down-regulation of COX-1 (Ptgs1) and PGI synthase (Ptgis), leading to reduced PGI2 production. Treatment with the PGI2 analog iloprost rescues defects in myotube formation, migration, and fusion, placing ARID5B upstream of the prostanoid biosynthesis pathway in myogenesis.","method":"Primary cell isolation from Arid5b-/- mice, microarray, RT-PCR, Western blot, ELISA (PGI2), Boyden chamber migration assay, iloprost rescue experiment","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (microarray, RT-PCR, ELISA, functional rescue) in KO cells establishing pathway position; single lab","pmids":["29196500"],"is_preprint":false},{"year":2020,"finding":"Arid5b knockout in skeletal muscle leads to increased basal glucose uptake, glycogen content, glucose oxidation, and ATP production. The mechanistic basis involves downregulation of TBC1D1 (a negative regulator of GLUT4 translocation), resulting in increased GLUT4 localization at the plasma membrane in Arid5b-/- muscle.","method":"Arid5b-/- mouse skeletal muscle analysis, glucose uptake assays, glycogen measurements, coimmunofluorescence for GLUT4/dystrophin, protein expression analysis","journal":"Biological research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — KO model with multiple metabolic readouts and GLUT4 localization by immunofluorescence; single lab","pmids":["33023658"],"is_preprint":false},{"year":2021,"finding":"Fabp4-Cre conditional Arid5b knockout mice (adipocyte-specific) are resistant to high-fat diet-induced weight gain, with decreased lipid accumulation specifically in subcutaneous (inguinal) white adipose tissue and liver, but not in gonadal WAT. RNA-seq revealed decreased expression of inflammation-associated genes in IWAT adipocytes of FSKO mice, suggesting ARID5B regulates inflammatory signaling from specific WAT depots to the liver.","method":"Conditional Fabp4-Cre; Arid5bFLOX/FLOX mouse generation, HFD challenge, tissue weight, triglyceride measurements, CD68 staining for macrophages, RNA-seq","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with multiple phenotypic readouts and RNA-seq; single lab","pmids":["33757861"],"is_preprint":false},{"year":2022,"finding":"ARID5B risk variants at the ALL susceptibility locus function through cis-regulatory elements. CRISPR-based enhancer screening identified six cis-regulatory elements at the ARID5B locus. The top ALL risk variant (rs7090445) lies within the strongest enhancer, which is distally tethered to the ARID5B promoter. The risk allele disrupts the MEF2C binding motif, reducing MEF2C affinity and decreasing local chromatin accessibility. MEF2C influences ARID5B expression in ALL, likely via a transcription factor complex with RUNX1.","method":"dCas9-KRAB enhancer interference screening, chromatin immunoprecipitation (ChIP), coimmunoprecipitation (MEF2C-RUNX1 complex), ATAC-seq (chromatin accessibility), targeted sequencing, UK Biobank genetic analysis","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR-based enhancer screen, ChIP, Co-IP, ATAC-seq; multiple orthogonal methods establishing the molecular mechanism of risk variant action","pmids":["35575404"],"is_preprint":false},{"year":2023,"finding":"ARID5B-PHF2 complex promotes histone demethylation at H3K36me2 at the SORBS2 promoter, thereby activating SORBS2 transcription and suppressing epithelial-to-mesenchymal transition (EMT) and tumor generation in ovarian cancer cells.","method":"ChIP (H3K36me2 at SORBS2 promoter), ARID5B overexpression/knockdown, Co-immunoprecipitation, in vivo and in vitro functional assays for EMT","journal":"Pathology, research and practice","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and Co-IP with functional readout for EMT; single lab with two orthogonal methods","pmids":["37948999"],"is_preprint":false},{"year":2023,"finding":"ARID5B regulates B cell development at the Pre-B cell stage: Arid5b deletion in vivo and ex vivo causes increased large and small Pre-B cell proportions with enhanced proliferation, and enhanced fatty acid uptake and oxidation at the Pre-B stage. ARID5B expression is upregulated at the Pre-B stage and maintained through later B cell development.","method":"In vivo Arid5b conditional knockout and ex vivo Arid5b inhibition; flow cytometry for B cell fractions; metabolic assays (fatty acid uptake, oxidation); gene expression analysis in mouse and human bone marrow","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO and ex vivo inhibition with multiple readouts (flow cytometry, metabolic assays); single lab","pmids":["37483604"],"is_preprint":false},{"year":2023,"finding":"Arid5b overexpression in mice (Vav1-driven transgenic) causes a dramatic reduction in circulating B cells and B cell fractions in peripheral blood, bone marrow, and spleen. ARID5B overexpression leads to defects in B cell activation in vitro with hyperactivation of B-cell receptor signaling at baseline, and increases mitochondrial oxygen consumption rate in naïve and stimulated B cells.","method":"Vav1-Cre transgenic mouse overexpression, flow cytometry, in vitro B cell activation assays, mitochondrial oxygen consumption rate measurement","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo overexpression model with multiple functional readouts; single lab","pmids":["35924577"],"is_preprint":false},{"year":2023,"finding":"Muscle-specific deletion of Arid5b leads to preferential utilization of fatty acids for energy generation in skeletal muscle, decreased adipose tissue weight (via increased phospho-HSL/HSL in WAT), and glucose diversion into the pentose phosphate pathway and glycolysis for lactate export. Glucose oxidation is reduced in conjunction with downregulation of the mitochondrial pyruvate carrier (MPC). This establishes ARID5B as a regulator of fuel selection in skeletal muscle that systemically influences adipose and liver metabolism.","method":"Skeletal muscle-specific Arid5b knockout (Arid5b MKO) mice, metabolic phenotyping, gene expression analysis, tissue weight measurements","journal":"Frontiers in endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with multiple metabolic readouts; single lab","pmids":["36743919"],"is_preprint":false},{"year":2024,"finding":"ARID5B directly activates LINC01128 transcription by binding to its promoter (confirmed by ChIP). The long isoform of ARID5B is negatively regulated by TNF-α in rheumatoid arthritis synovial fibroblasts, and suppresses IL-6 production stimulated by TNF-α. siRNA knockdown and lentiviral overexpression of ARID5B isoforms confirmed the long isoform as a negative modulator of IL-6.","method":"siRNA knockdown, lentiviral overexpression, luciferase reporter assay, RNA immunoprecipitation, RNA pulldown, co-immunoprecipitation, ChIP","journal":"Clinical and translational medicine / Immunological medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP for direct promoter binding, KD and OE with functional readout; two independent papers with overlapping evidence","pmids":["38224186","38747454"],"is_preprint":false},{"year":2025,"finding":"ARID5B assembles into a chromatin repressor complex with MIER1, C16ORF87, HDAC1, and HDAC2 in B-ALL cells. CUT&RUN mapping showed ARID5B binds active regions of the genome and tethers HDAC1/HDAC2 to distal regulatory elements and promoters. Genes actively repressed by this ARID5B complex are involved in B cell proliferation and B cell-specific signaling.","method":"Proteomics (mass spectrometry for complex identification), CUT&RUN (ARID5B, HDAC1, HDAC2 genome-wide binding), RNA-seq (transcriptomic effects)","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proteomics for complex identification plus CUT&RUN genomics; preprint, not yet peer-reviewed; multiple orthogonal methods","pmids":["bio_10.1101_2025.10.17.683040"],"is_preprint":true},{"year":2025,"finding":"In epileptogenesis, WDR5 enhances H3K4me3 deposition at the Arid5b promoter, driving transcriptional upregulation of ARID5B in hippocampal neurons. The upregulated ARID5B subsequently represses GABA-A receptor (GABAAR) subunit expression, impairing inhibitory synaptic transmission and facilitating epileptogenesis.","method":"ChIP-seq (H3K4me3 at Arid5b promoter), RNA-seq, WDR5 knockdown, neuron-specific WDR5 knockout, whole-cell patch-clamp recordings, video-EEG monitoring","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq, KO with electrophysiology and EEG readouts; single lab with multiple orthogonal methods","pmids":["41510154"],"is_preprint":false},{"year":2025,"finding":"ApoM upregulates Arid5b expression in hepatocytes, and Arid5b knockdown increases culture-medium prothrombin levels while decreasing cellular prothrombin levels, reversing ApoM's inhibitory effect on prothrombin secretion. This places ARID5B downstream of ApoM in regulation of hepatic prothrombin secretion, independent of S1P receptors.","method":"RNA-seq (Arid5b identification), Arid5b knockdown in HepG2 cells, ApoM overexpression/knockout mouse models, prothrombin ELISA","journal":"Thrombosis and haemostasis","confidence":"Low","confidence_rationale":"Tier 3 / Weak — RNA-seq for target identification, single KD experiment with functional readout; single lab, limited mechanistic depth","pmids":["40719152"],"is_preprint":false},{"year":2024,"finding":"Two transcriptionally distinct ARID5B isoforms (short and long) differ in an encoded BAH-like chromatin interaction domain. Both isoforms have functionally independent proximal promoters as shown by luciferase reporter assays. Increased short isoform expression is associated with decreased event-free and overall survival in B-ALL, and the isoform ratio strongly correlates with B-ALL prognostic stratification.","method":"RNA-seq splice junction analysis, luciferase reporter assays for independent promoter activity, correlation with clinical survival outcomes","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase assay for promoter activity is mechanistic, but the functional consequence of isoform difference is correlative; single lab, limited mechanistic follow-up","pmids":["38382358"],"is_preprint":false}],"current_model":"ARID5B is an AT-rich DNA-binding transcriptional co-regulator that functions primarily as a scaffold/DNA-targeting subunit for epigenetic complexes: it assembles with the H3K9me2 demethylase PHF2 (activated by PKA-mediated phosphorylation) to direct H3K9me2 removal at target promoters and activate transcription, and separately assembles with HDAC1/HDAC2/MIER1 to form a chromatin repressor complex at active regulatory elements; it also interacts with Sox9 to promote chondrogenesis, is regulated by Ikaros and MEF2C/RUNX1 at its own cis-regulatory elements, controls prostanoid biosynthesis (PGI2) and fatty acid/glucose metabolism in muscle, and suppresses IL-6 production in synovial fibroblasts, with its long and short isoforms having distinct promoters and potentially distinct chromatin-interaction functions relevant to B-ALL leukemogenesis."},"narrative":{"mechanistic_narrative":"ARID5B is an AT-rich interaction domain (ARID) transcription factor that functions as a sequence-specific DNA-targeting subunit for chromatin-modifying complexes, coupling promoter recognition to histone demethylation and deacetylation to control cell differentiation and metabolism [PMID:21532585, PMID:10329386]. Its ARID domain recognizes the core AATA(C/T) motif through major- and minor-groove contacts, with two flexible interhelical loops (L1, L2) mediating phosphate-backbone and AT base-pair contacts [PMID:10329386, PMID:17407261]. Mechanistically, ARID5B associates with the PKA-activated H3K9me2 demethylase PHF2 and targets this complex to promoters to erase repressive methyl marks and activate transcription [PMID:21532585]; this ARID5B–PHF2 module promotes chondrocyte differentiation through Sox9 target genes [PMID:24276541] and activates SORBS2 to suppress epithelial-to-mesenchymal transition [PMID:37948999]. In an opposing capacity, ARID5B assembles a chromatin repressor complex with MIER1, C16ORF87, HDAC1 and HDAC2, tethering deacetylase activity to active distal regulatory elements and promoters to repress B-cell proliferation and signaling genes [PMID:bio_10.1101_2025.10.17.683040]. ARID5B is a central regulator of fuel selection and lipid storage: knockout mice show defective brown/white adipose lipid accumulation and resistance to diet-induced obesity [PMID:14651970, PMID:33757861], and muscle-specific loss reprograms substrate use through control of prostanoid (PGI2) biosynthesis, GLUT4/TBC1D1-dependent glucose handling, and mitochondrial pyruvate transport [PMID:29196500, PMID:33023658, PMID:36743919]. In hematopoiesis, ARID5B governs Pre-B cell expansion and metabolism [PMID:37483604, PMID:35924577], and acts as a collaborating oncogenic factor by co-occupying genomic targets with the TAL1 complex and activating MYC in T-ALL [PMID:29326336]. ARID5B's own expression is set by lineage transcription factors and enhancer variants, including Ikaros [PMID:30420689] and a MEF2C/RUNX1-bound enhancer harboring an ALL risk allele [PMID:35575404].","teleology":[{"year":1999,"claim":"Established the DNA recognition specificity of the ARID5B ARID domain, defining how this factor selects genomic targets.","evidence":"Binding interference, site-selection, and kinetic assays with base-analogue oligonucleotides","pmids":["10329386"],"confidence":"High","gaps":["Does not identify in vivo target genes","Affinity determinants do not explain promoter selectivity in chromatin context"]},{"year":2001,"claim":"Showed that protein dynamics, not just static structure, drive ARID-domain DNA binding, resolving how flexible loops engage the duplex.","evidence":"15N NMR relaxation and chemical shift perturbation mapping of the isolated ARID domain","pmids":["11478881"],"confidence":"High","gaps":["No bound complex structure in this study","Full-length protein dynamics not addressed"]},{"year":2003,"claim":"Defined the first organismal role for ARID5B, establishing it as essential for postnatal lipid accumulation and adiposity.","evidence":"Mrf2/Arid5b knockout mouse phenotyping with high-fat diet challenge","pmids":["14651970"],"confidence":"High","gaps":["Does not identify the transcriptional targets controlling lipid storage","Tissue of action not resolved"]},{"year":2007,"claim":"Provided the structural basis of ARID5B–DNA recognition, mapping which loops and helices contact AT base pairs.","evidence":"NMR structure of the ARID domain–DNA complex using paramagnetic spin-label constraints and docking","pmids":["17407261"],"confidence":"High","gaps":["Isolated domain only; no full-length or co-factor-bound structure","Does not link recognition to transcriptional output"]},{"year":2011,"claim":"Revealed the core enzymatic mechanism by which ARID5B activates transcription—recruiting PKA-activated PHF2 to demethylate H3K9me2 at promoters.","evidence":"Co-IP, in vitro demethylase assays, ChIP, and PKA phosphorylation/mutagenesis","pmids":["21532585"],"confidence":"High","gaps":["Promoter targeting specificity in vivo not defined","Does not address ARID5B-only or repressive functions"]},{"year":2013,"claim":"Connected the ARID5B–PHF2 demethylase module to a developmental program by showing it cooperates with Sox9 to drive chondrogenesis.","evidence":"Reciprocal Co-IP with Sox9, ChIP for H3K9me2, Arid5b-/- mouse phenotyping, and PHF2 knockdown rescue","pmids":["24276541"],"confidence":"High","gaps":["Direct ARID5B binding to Sox9-target promoters not mapped genome-wide","Whether Sox9 recruits ARID5B or vice versa unresolved"]},{"year":2018,"claim":"Identified ARID5B as a collaborating oncogenic transcription factor in T-ALL that partners genomically with TAL1 and activates MYC.","evidence":"ChIP-seq co-occupancy with TAL1, knockdown/overexpression, and zebrafish thymocyte tumor model","pmids":["29326336"],"confidence":"High","gaps":["Whether ARID5B uses its demethylase or repressor partners in this context unknown","Mechanism of MYC activation not resolved"]},{"year":2018,"claim":"Linked ARID5B expression control to the Ikaros tumor suppressor and confirmed its PHF2 interaction in ALL cells.","evidence":"Co-IP, CK2 inhibition, and ChIP for H3K4me3 at the ARID5B promoter","pmids":["30420689"],"confidence":"Medium","gaps":["Two orthogonal methods from a single lab","Functional consequence of Ikaros-driven ARID5B levels not tested"]},{"year":2018,"claim":"Extended ARID5B function to immune-cell metabolism, showing a hypomethylation-induced short isoform drives oxidative metabolism and effector function in adaptive NK cells.","evidence":"siRNA knockdown/overexpression in human NK cells with mitochondrial, respiration, and IFN-γ readouts plus bisulfite sequencing","pmids":["30061358"],"confidence":"High","gaps":["Transcriptional targets driving the metabolic phenotype not identified","Isoform-specific mechanism not resolved"]},{"year":2018,"claim":"Placed ARID5B upstream of prostanoid biosynthesis in muscle differentiation by linking it to COX-1/PGI synthase and PGI2.","evidence":"Arid5b-/- primary muscle cells, microarray, PGI2 ELISA, and iloprost rescue of myogenesis defects","pmids":["29196500"],"confidence":"High","gaps":["Whether ARID5B directly binds Ptgs1/Ptgis promoters not shown","Direct vs indirect regulation unresolved"]},{"year":2020,"claim":"Defined a glucose-handling axis whereby ARID5B restrains GLUT4 surface localization via TBC1D1 in muscle.","evidence":"Arid5b-/- muscle glucose uptake/glycogen assays and GLUT4 immunofluorescence","pmids":["33023658"],"confidence":"Medium","gaps":["Direct transcriptional control of TBC1D1 not demonstrated","Single-lab metabolic study"]},{"year":2021,"claim":"Showed ARID5B acts in a depot-specific manner in adipocytes, controlling subcutaneous WAT/liver lipid storage and inflammatory gene programs.","evidence":"Adipocyte-specific Fabp4-Cre Arid5b knockout with HFD challenge, triglyceride, macrophage staining, and RNA-seq","pmids":["33757861"],"confidence":"Medium","gaps":["Mechanism of depot selectivity unknown","Direct inflammatory-gene targets not validated"]},{"year":2022,"claim":"Explained how an inherited ALL risk variant acts mechanistically, by disrupting a MEF2C/RUNX1 enhancer that controls ARID5B expression.","evidence":"dCas9-KRAB enhancer screen, ChIP, MEF2C-RUNX1 Co-IP, ATAC-seq, and UK Biobank analysis","pmids":["35575404"],"confidence":"High","gaps":["Downstream leukemogenic consequence of altered ARID5B dosage not directly tested here","Other enhancers' contributions unquantified"]},{"year":2023,"claim":"Broadened the demethylase activity of ARID5B–PHF2 to H3K36me2 and tumor suppression, activating SORBS2 to block EMT in ovarian cancer.","evidence":"ChIP for H3K36me2 at SORBS2, ARID5B OE/KD, Co-IP, and EMT functional assays","pmids":["37948999"],"confidence":"Medium","gaps":["Single-lab study with two orthogonal methods","How substrate specificity switches between H3K9me2 and H3K36me2 unresolved"]},{"year":2023,"claim":"Established ARID5B as a regulator of Pre-B cell expansion and metabolism, with dosage controlling B-cell output bidirectionally.","evidence":"Conditional knockout and ex vivo inhibition plus Vav1-driven overexpression, flow cytometry, BCR signaling, and metabolic/OCR assays","pmids":["37483604","35924577"],"confidence":"Medium","gaps":["Direct transcriptional targets in B cells not defined","Link between metabolic and proliferative phenotypes mechanistically unresolved"]},{"year":2023,"claim":"Detailed how muscle ARID5B sets systemic fuel selection, controlling pyruvate oxidation and glucose partitioning with effects on adipose and liver.","evidence":"Skeletal-muscle-specific Arid5b knockout with metabolic phenotyping and gene expression","pmids":["36743919"],"confidence":"Medium","gaps":["Direct targets (e.g., MPC) not validated as ARID5B-bound","Inter-organ signaling mediator unknown"]},{"year":2024,"claim":"Defined ARID5B isoform architecture, identifying short/long isoforms with distinct BAH-like chromatin domains, independent promoters, and prognostic relevance in B-ALL.","evidence":"RNA-seq splice analysis, luciferase promoter assays, and clinical survival correlation","pmids":["38382358"],"confidence":"Low","gaps":["Functional consequence of the isoform difference is correlative, not mechanistic","Chromatin role of the BAH-like domain not tested directly"]},{"year":2024,"claim":"Revealed an inflammatory regulatory role in which the ARID5B long isoform, suppressed by TNF-α, dampens IL-6 and directly activates LINC01128 in synovial fibroblasts.","evidence":"siRNA/lentiviral isoform manipulation, luciferase, RIP, RNA pulldown, Co-IP, and ChIP for promoter binding","pmids":["38224186","38747454"],"confidence":"Medium","gaps":["Mechanism by which the long isoform suppresses IL-6 not fully defined","Role of LINC01128 downstream unresolved"]},{"year":2025,"claim":"Identified ARID5B as the DNA-targeting subunit of a MIER1/HDAC1/HDAC2 repressor complex, providing a deacetylase-based repressive mechanism distinct from its demethylase activity.","evidence":"Mass spectrometry proteomics, CUT&RUN for genome-wide binding, and RNA-seq in B-ALL cells (preprint)","pmids":["bio_10.1101_2025.10.17.683040"],"confidence":"Medium","gaps":["Preprint, not yet peer-reviewed","How ARID5B switches between activating and repressive complexes unknown"]},{"year":2025,"claim":"Connected ARID5B to neuronal excitability, showing WDR5-driven ARID5B upregulation represses GABA-A receptor subunits to promote epileptogenesis.","evidence":"ChIP-seq for H3K4me3, RNA-seq, WDR5 knockdown/neuronal knockout, patch-clamp, and video-EEG","pmids":["41510154"],"confidence":"Medium","gaps":["Whether ARID5B binds GABAAR subunit promoters directly not shown","Which ARID5B partner complex mediates repression here unknown"]},{"year":2025,"claim":"Placed ARID5B in hepatic coagulation control as a downstream effector of ApoM regulating prothrombin secretion.","evidence":"RNA-seq target identification, Arid5b knockdown in HepG2, ApoM mouse models, and prothrombin ELISA","pmids":["40719152"],"confidence":"Low","gaps":["Single knockdown with limited mechanistic depth","Direct transcriptional targets in hepatocytes not identified"]},{"year":null,"claim":"It remains unknown what governs the switch between ARID5B's activating (PHF2 demethylase) and repressive (MIER1/HDAC) complexes, and how isoform identity and the BAH-like domain dictate which complex assembles at a given locus.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of full-length ARID5B with either partner complex","Isoform-specific complex assembly not directly tested","Determinants of context-dependent activation vs repression unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,3,4,0,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[7,1,13,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,18,1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,18,7]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,7,17]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,18,1]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,9,10,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,12,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,9,14]}],"complexes":["ARID5B-PHF2 demethylase complex","ARID5B-MIER1-HDAC1-HDAC2 repressor complex"],"partners":["PHF2","SOX9","TAL1","MIER1","HDAC1","HDAC2","C16ORF87"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14865","full_name":"AT-rich interactive domain-containing protein 5B","aliases":["MRF1-like protein","Modulator recognition factor 2","MRF-2"],"length_aa":1188,"mass_kda":132.4,"function":"Transcription coactivator that binds to the 5'-AATA[CT]-3' core sequence and plays a key role in adipogenesis and liver development. Acts by forming a complex with phosphorylated PHF2, which mediates demethylation at Lys-336, leading to target the PHF2-ARID5B complex to target promoters, where PHF2 mediates demethylation of dimethylated 'Lys-9' of histone H3 (H3K9me2), followed by transcription activation of target genes. The PHF2-ARID5B complex acts as a coactivator of HNF4A in liver. Required for adipogenesis: regulates triglyceride metabolism in adipocytes by regulating expression of adipogenic genes. Overexpression leads to induction of smooth muscle marker genes, suggesting that it may also act as a regulator of smooth muscle cell differentiation and proliferation. Represses the cytomegalovirus enhancer","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q14865/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID5B","classification":"Not Classified","n_dependent_lines":21,"n_total_lines":1208,"dependency_fraction":0.0173841059602649},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HDAC1","stoichiometry":0.2},{"gene":"HDAC2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ARID5B","total_profiled":1310},"omim":[{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"612985","title":"IROQUOIS HOMEOBOX PROTEIN 3; IRX3","url":"https://www.omim.org/entry/612985"},{"mim_id":"612460","title":"BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 14; BMIQ14","url":"https://www.omim.org/entry/612460"},{"mim_id":"612457","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3B; ARID3B","url":"https://www.omim.org/entry/612457"},{"mim_id":"610966","title":"FTO ALPHA-KETOGLUTARATE-DEPENDENT DIOXYGENASE; FTO","url":"https://www.omim.org/entry/610966"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":83.9}],"url":"https://www.proteinatlas.org/search/ARID5B"},"hgnc":{"alias_symbol":["FLJ21150","MRF2"],"prev_symbol":[]},"alphafold":{"accession":"Q14865","domains":[{"cath_id":"2.30.30.490","chopping":"8-245","consensus_level":"high","plddt":80.0636,"start":8,"end":245},{"cath_id":"1.10.150.60","chopping":"325-411","consensus_level":"high","plddt":88.9893,"start":325,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14865","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14865-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14865-F1-predicted_aligned_error_v6.png","plddt_mean":50.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID5B","jax_strain_url":"https://www.jax.org/strain/search?query=ARID5B"},"sequence":{"accession":"Q14865","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14865.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14865/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14865"}},"corpus_meta":[{"pmid":"23273568","id":"PMC_23273568","title":"Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23273568","citation_count":175,"is_preprint":false},{"pmid":"21532585","id":"PMC_21532585","title":"PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B.","date":"2011","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21532585","citation_count":154,"is_preprint":false},{"pmid":"30061358","id":"PMC_30061358","title":"ARID5B regulates metabolic programming in human adaptive NK cells.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30061358","citation_count":107,"is_preprint":false},{"pmid":"24276541","id":"PMC_24276541","title":"Arid5b facilitates chondrogenesis by recruiting the histone demethylase Phf2 to Sox9-regulated genes.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24276541","citation_count":80,"is_preprint":false},{"pmid":"20460642","id":"PMC_20460642","title":"Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia.","date":"2010","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/20460642","citation_count":64,"is_preprint":false},{"pmid":"29326336","id":"PMC_29326336","title":"ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/29326336","citation_count":55,"is_preprint":false},{"pmid":"10329386","id":"PMC_10329386","title":"The novel Mrf-2 DNA-binding domain recognizes a five-base core sequence through major and minor-groove contacts.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10329386","citation_count":52,"is_preprint":false},{"pmid":"21889209","id":"PMC_21889209","title":"Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.","date":"2011","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/21889209","citation_count":49,"is_preprint":false},{"pmid":"14651970","id":"PMC_14651970","title":"Neonatal mortality and leanness in mice lacking the ARID transcription factor Mrf-2.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14651970","citation_count":49,"is_preprint":false},{"pmid":"23608171","id":"PMC_23608171","title":"Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23608171","citation_count":47,"is_preprint":false},{"pmid":"23836053","id":"PMC_23836053","title":"Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics.","date":"2013","source":"Cancer causes & control : CCC","url":"https://pubmed.ncbi.nlm.nih.gov/23836053","citation_count":41,"is_preprint":false},{"pmid":"11478881","id":"PMC_11478881","title":"Dynamics of the Mrf-2 DNA-binding domain free and in complex with DNA.","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11478881","citation_count":33,"is_preprint":false},{"pmid":"24200646","id":"PMC_24200646","title":"High-resolution melting analyses for genetic variants in ARID5B and IKZF1 with childhood acute lymphoblastic leukemia susceptibility loci in Taiwan.","date":"2013","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24200646","citation_count":33,"is_preprint":false},{"pmid":"32595701","id":"PMC_32595701","title":"The Role of ARID5B in Acute Lymphoblastic Leukemia and Beyond.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32595701","citation_count":30,"is_preprint":false},{"pmid":"17407261","id":"PMC_17407261","title":"Determination of the three-dimensional structure of the Mrf2-DNA complex using paramagnetic spin labeling.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17407261","citation_count":30,"is_preprint":false},{"pmid":"24712521","id":"PMC_24712521","title":"Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24712521","citation_count":30,"is_preprint":false},{"pmid":"25310577","id":"PMC_25310577","title":"Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25310577","citation_count":29,"is_preprint":false},{"pmid":"30420689","id":"PMC_30420689","title":"Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30420689","citation_count":25,"is_preprint":false},{"pmid":"35575404","id":"PMC_35575404","title":"Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia.","date":"2022","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/35575404","citation_count":21,"is_preprint":false},{"pmid":"23975371","id":"PMC_23975371","title":"ARID5B gene rs10821936 polymorphism is associated with childhood acute lymphoblastic leukemia: a meta-analysis based on 39,116 subjects.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23975371","citation_count":21,"is_preprint":false},{"pmid":"24013273","id":"PMC_24013273","title":"Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility.","date":"2013","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24013273","citation_count":19,"is_preprint":false},{"pmid":"28381164","id":"PMC_28381164","title":"Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28381164","citation_count":17,"is_preprint":false},{"pmid":"22971728","id":"PMC_22971728","title":"Associations of variations in the MRF2/ARID5B gene with susceptibility to type 2 diabetes in the Japanese population.","date":"2012","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22971728","citation_count":16,"is_preprint":false},{"pmid":"29196500","id":"PMC_29196500","title":"Reduced prostaglandin I2 signaling in Arid5b-/- primary skeletal muscle cells attenuates myogenesis.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29196500","citation_count":14,"is_preprint":false},{"pmid":"31704777","id":"PMC_31704777","title":"Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor.","date":"2019","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31704777","citation_count":14,"is_preprint":false},{"pmid":"31227872","id":"PMC_31227872","title":"Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.","date":"2019","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31227872","citation_count":12,"is_preprint":false},{"pmid":"33023658","id":"PMC_33023658","title":"Increased glucose metabolism in Arid5b-/- skeletal muscle is associated with the down-regulation of TBC1 domain family member 1 (TBC1D1).","date":"2020","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/33023658","citation_count":12,"is_preprint":false},{"pmid":"31111395","id":"PMC_31111395","title":"ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis.","date":"2019","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/31111395","citation_count":10,"is_preprint":false},{"pmid":"37948999","id":"PMC_37948999","title":"ARID5B promoted the histone demethylation of SORBS2 and hampered the metastasis of ovarian cancer.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37948999","citation_count":10,"is_preprint":false},{"pmid":"33757861","id":"PMC_33757861","title":"Mice with Fabp4-Cre ablation of Arid5b are resistant to diet-induced obesity and hepatic steatosis.","date":"2021","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33757861","citation_count":10,"is_preprint":false},{"pmid":"35924577","id":"PMC_35924577","title":"ARID5B influences B-cell development and function in mouse.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/35924577","citation_count":9,"is_preprint":false},{"pmid":"38224186","id":"PMC_38224186","title":"ARID5B-mediated LINC01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the BTF3/STAT3 complex in β2GPI/anti-β2GPI-treated monocytes.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38224186","citation_count":8,"is_preprint":false},{"pmid":"34265779","id":"PMC_34265779","title":"Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes.","date":"2021","source":"Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34265779","citation_count":8,"is_preprint":false},{"pmid":"18612189","id":"PMC_18612189","title":"Genetic variations of Mrf-2/ARID5B confer risk of coronary atherosclerosis in the Japanese population.","date":"2008","source":"International heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/18612189","citation_count":8,"is_preprint":false},{"pmid":"30810385","id":"PMC_30810385","title":"Association of ARID5B and IKZF1 Variants with Leukemia from Northern India.","date":"2019","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/30810385","citation_count":7,"is_preprint":false},{"pmid":"31867206","id":"PMC_31867206","title":"Association of genes ARID5B, CEBPE and folate pathway with acute lymphoblastic leukemia in a population from the Brazilian Amazon region.","date":"2019","source":"Leukemia research reports","url":"https://pubmed.ncbi.nlm.nih.gov/31867206","citation_count":7,"is_preprint":false},{"pmid":"31424309","id":"PMC_31424309","title":"ARID5B rs10821936 and rs10994982 gene polymorphisms and acute lymphoblastic leukemia: relation to disease susceptibility and outcome.","date":"2019","source":"Pediatric hematology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31424309","citation_count":6,"is_preprint":false},{"pmid":"35205374","id":"PMC_35205374","title":"Impact of Variants in the ATIC and ARID5B Genes on Therapeutic Failure with Imatinib in Patients with Chronic Myeloid Leukemia.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35205374","citation_count":6,"is_preprint":false},{"pmid":"36743919","id":"PMC_36743919","title":"Muscle-specific deletion of Arid5b causes metabolic changes in skeletal muscle that affect adipose tissue and liver.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36743919","citation_count":5,"is_preprint":false},{"pmid":"33499894","id":"PMC_33499894","title":"Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33499894","citation_count":5,"is_preprint":false},{"pmid":"29373897","id":"PMC_29373897","title":"Association of ARID5B Genetic Variants with Risk of Childhood B Cell Precursor Acute Lymphoblastic Leukaemia in Latvia.","date":"2018","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/29373897","citation_count":5,"is_preprint":false},{"pmid":"28781666","id":"PMC_28781666","title":"Molecular studies reveal MLL-MLLT10/AF10 and ARID5B-MLL gene fusions displaced in a case of infantile acute lymphoblastic leukemia with complex karyotype.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28781666","citation_count":5,"is_preprint":false},{"pmid":"33888010","id":"PMC_33888010","title":"ARID5B rs10821936 and rs10994982 gene polymorphism and susceptibility to juvenile systemic lupus erythematosus and lupus nephritis.","date":"2021","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/33888010","citation_count":4,"is_preprint":false},{"pmid":"34803080","id":"PMC_34803080","title":"Genetic association of ARID5B with the risk of colorectal cancer within Jammu and Kashmir, India.","date":"2021","source":"Genes & genetic systems","url":"https://pubmed.ncbi.nlm.nih.gov/34803080","citation_count":4,"is_preprint":false},{"pmid":"37483604","id":"PMC_37483604","title":"ARID5B regulates fatty acid metabolism and proliferation at the Pre-B cell stage during B cell development.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37483604","citation_count":3,"is_preprint":false},{"pmid":"38747454","id":"PMC_38747454","title":"ARID5B is a negative modulator of IL-6 production in rheumatoid arthritis synovial fibroblasts.","date":"2024","source":"Immunological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38747454","citation_count":3,"is_preprint":false},{"pmid":"36952466","id":"PMC_36952466","title":"Contributions of ARID5B, IKZF1, PIP4K2A, and GATA3 Gene Polymorphisms to Childhood Acute Lymphoblastic Leukemia in a Chinese Population.","date":"2023","source":"Journal of pediatric hematology/oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36952466","citation_count":3,"is_preprint":false},{"pmid":"25354457","id":"PMC_25354457","title":"Differential expression of arid5b isoforms in Xenopus laevis pronephros.","date":"2014","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25354457","citation_count":3,"is_preprint":false},{"pmid":"37578068","id":"PMC_37578068","title":"ARID5B, IKZF1, GATA3, CEBPE, and CDKN2A germline polymorphisms and predisposition to childhood acute lymphoblastic leukemia.","date":"2023","source":"Pediatric hematology and oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37578068","citation_count":3,"is_preprint":false},{"pmid":"35444070","id":"PMC_35444070","title":"Hsa-miR-422a Originated from Short Interspersed Nuclear Element Increases ARID5B Expression by Collaborating with NF-E2.","date":"2022","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/35444070","citation_count":3,"is_preprint":false},{"pmid":"25808444","id":"PMC_25808444","title":"Rs4948496 within ARID5B gene is associated with clinical features of systemic lupus erythematosus in the Chinese Han population.","date":"2015","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25808444","citation_count":3,"is_preprint":false},{"pmid":"36708585","id":"PMC_36708585","title":"Association of two ARID5B gene variant single nucleotide polymorphisms with acute lymphoblastic leukemia in the Egyptian population.","date":"2023","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/36708585","citation_count":2,"is_preprint":false},{"pmid":"35939970","id":"PMC_35939970","title":"Hsa_circ_0102485 inhibits the growth of cancer cells by regulating the miR-188-3p/ARID5B/AR axis in prostate carcinoma.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35939970","citation_count":2,"is_preprint":false},{"pmid":"23114164","id":"PMC_23114164","title":"[Research advances on correlation of ARID5B gene with childhood acute lymphoblastic leukemia - review].","date":"2012","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/23114164","citation_count":1,"is_preprint":false},{"pmid":"38738968","id":"PMC_38738968","title":"Constitutional and acquired genetic variants in ARID5B in pediatric B-cell precursor acute lymphoblastic leukemia.","date":"2024","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38738968","citation_count":0,"is_preprint":false},{"pmid":"37096502","id":"PMC_37096502","title":"[Correlation between ARID5B Gene SNP and MTX Resistance in Children with ALL].","date":"2023","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/37096502","citation_count":0,"is_preprint":false},{"pmid":"41510154","id":"PMC_41510154","title":"Neuron-specific WDR5 epigenetically upregulates ARID5B to impair GABAergic synaptic transmission and promotes epileptogenesis.","date":"2026","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/41510154","citation_count":0,"is_preprint":false},{"pmid":"38382358","id":"PMC_38382358","title":"Identification of an alternative short ARID5B isoform associated with B-ALL survival.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/38382358","citation_count":0,"is_preprint":false},{"pmid":"40719152","id":"PMC_40719152","title":"Hepatic Apolipoprotein M Suppresses Hepatocyte Secretion of Prothrombin by Upregulating Arid5B.","date":"2025","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/40719152","citation_count":0,"is_preprint":false},{"pmid":"41234072","id":"PMC_41234072","title":"[Correlation of ARID5B Gene Polymorphism and Risk of Childhood Acute Lymphoblastic Leukemia and Minimal Residual Disease].","date":"2025","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/41234072","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.17.683040","title":"Leukemia Risk Factor ARID5B Coordinates HDAC-Mediated Transcriptional Repression","date":"2025-10-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.17.683040","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.27.641500","title":"A factor-based analysis of individual human microglia uncovers regulators of an Alzheimer-related transcriptional signature","date":"2025-03-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.27.641500","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.29.630486","title":"H3K4-H3K9 Histone Methylation Patterns and Oncofetal Developmental Networks as Drivers of Cell Fate Decisions in Pediatric High-Grade Gliomas","date":"2024-12-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.29.630486","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33615,"output_tokens":6024,"usd":0.095603,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14804,"output_tokens":5893,"usd":0.110672,"stage2_stop_reason":"end_turn"},"total_usd":0.206275,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"ARID5B forms a histone demethylase complex with PHF2. PHF2 is enzymatically inactive alone but becomes an active H3K9Me2 demethylase upon PKA-mediated phosphorylation; phosphorylated PHF2 then associates with ARID5B (a DNA-binding protein), and ARID5B itself is demethylated. The PHF2-ARID5B complex is then targeted to promoters where it removes the repressive H3K9Me2 mark to activate transcription.\",\n      \"method\": \"Co-immunoprecipitation, in vitro demethylase assays, ChIP, PKA phosphorylation assays, mutagenesis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods including in vitro enzymatic assays, Co-IP, ChIP, and mutagenesis; replicated in subsequent papers\",\n      \"pmids\": [\"21532585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ARID5B physically associates with the transcription factor Sox9 and recruits the histone demethylase PHF2 to the promoter regions of Sox9 target genes, stimulating H3K9me2 demethylation and thereby promoting chondrocyte differentiation. Arid5b-/- mice show retarded growth and delayed endochondral ossification, and H3K9me2 levels are increased at chondrogenic marker gene promoters in Arid5b-deficient chondrocytes.\",\n      \"method\": \"Co-immunoprecipitation (physical association with Sox9), ChIP (H3K9me2 levels at promoters), Arid5b-/- mouse phenotyping, PHF2 knockdown rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, KO mouse with defined phenotype, and PHF2 knockdown rescue; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24276541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The ARID (MRF2/ARID5B) DNA-binding domain recognizes the core sequence AATA(C/T) through contacts in both major and minor grooves. Major groove contacts at positions 2, 3, and 4 of the core sequence are required for high-affinity binding, while positions 1 and 5 are contacted through the minor groove. The core sequence alone is not sufficient for high-affinity binding.\",\n      \"method\": \"Binding interference assays, binding site selection assays, kinetic analyses with synthetic oligonucleotides containing single base analogues\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple biochemical assays (interference, selection, kinetics with base analogues) establishing DNA recognition mechanism in one rigorous study\",\n      \"pmids\": [\"10329386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NMR backbone dynamics of the MRF2/ARID5B ARID domain show that two flexible interhelical loops (and the C-terminal tail) are involved in DNA recognition. Upon DNA binding, flexible loops show reduced mobility while some well-structured regions (including the putative DNA-contacting helix) show decreased order parameters, indicating that protein dynamics are integral to DNA binding.\",\n      \"method\": \"15N NMR relaxation measurements, model-free analysis, chemical shift perturbation mapping\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural and dynamics study with functional validation via chemical shift perturbation; single lab but rigorous structural method\",\n      \"pmids\": [\"11478881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The three-dimensional structure of the MRF2/ARID5B ARID domain in complex with target DNA was determined by NMR using paramagnetic spin-label distance constraints. MRF2 contacts DNA mainly through two flexible loops (L1 and L2): L1 contacts the phosphate backbone, while L2 and residues in adjacent helices interact with AT base pairs in the major groove.\",\n      \"method\": \"NMR spectroscopy with paramagnetic spin labeling, docking calculations\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure determination with spin-label distance constraints; single lab but rigorous structural methodology\",\n      \"pmids\": [\"17407261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Targeted disruption of Mrf2/Arid5b in mice results in high neonatal mortality, severely reduced lipid accumulation in brown adipose tissue in neonates, and lean adult phenotype with significant reductions in brown and white adipose tissues. Mrf2-/- mice are resistant to high-fat diet-induced obesity, demonstrating that ARID5B is essential for lipid accumulation in postnatal life.\",\n      \"method\": \"Mrf2-/- knockout mouse generation and phenotyping (body composition, adipose tissue histology, high-fat diet challenge)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with multiple defined phenotypic readouts (adipose tissue weight, lipid accumulation, body fat percentage, dietary challenge); replicated by subsequent conditional KO studies\",\n      \"pmids\": [\"14651970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A short isoform of ARID5B is selectively induced through DNA hypomethylation in adaptive (cytomegalovirus-expanded) NK cells. Knockdown and overexpression studies demonstrated that ARID5B directly promotes mitochondrial membrane potential, expression of genes encoding electron transport chain components, oxidative metabolism, survival, and IFN-γ production in these cells.\",\n      \"method\": \"ARID5B knockdown (siRNA) and overexpression in human NK cells; measurement of mitochondrial membrane potential, oxygen consumption rate, and IFN-γ production; bisulfite sequencing for DNA methylation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with multiple metabolic readouts, DNA methylation mapping, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"30061358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ARID5B is a direct transcriptional target of the TAL1 oncogenic complex in T-ALL and functions as a collaborating oncogenic factor. ARID5B co-occupies target genes with TAL1 and coordinately controls their expression. ARID5B positively regulates expression of TAL1 and its regulatory partners, and activates MYC expression. Forced expression of ARID5B in immature thymocytes causes thymus retention, differentiation arrest, radioresistance, and tumor formation in zebrafish.\",\n      \"method\": \"ChIP-seq (ARID5B and TAL1 co-occupancy), knockdown/overexpression studies, ARID5B forced expression in zebrafish thymocytes, superenhancer analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq for co-occupancy, KD and OE with defined phenotypes, in vivo zebrafish tumor model; multiple orthogonal methods\",\n      \"pmids\": [\"29326336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ARID5B physically interacts with PHF2 in acute lymphoblastic leukemia cells. Ikaros directly regulates ARID5B expression, and restoring Ikaros function via Casein Kinase II inhibition promotes ARID5B expression through recruitment of H3K4me3 at the ARID5B promoter.\",\n      \"method\": \"Co-immunoprecipitation (ARID5B-PHF2 interaction), CK2 inhibition with CK2i, ChIP (H3K4me3 at ARID5B promoter), gene expression analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP for interaction, ChIP for epigenetic regulation, CK2 inhibitor experiment; single lab with two orthogonal methods\",\n      \"pmids\": [\"30420689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Arid5b-/- primary skeletal muscle cells exhibit differentiation defects and impaired sarcomeric assembly. Mechanistically, Arid5b-/- cells show down-regulation of COX-1 (Ptgs1) and PGI synthase (Ptgis), leading to reduced PGI2 production. Treatment with the PGI2 analog iloprost rescues defects in myotube formation, migration, and fusion, placing ARID5B upstream of the prostanoid biosynthesis pathway in myogenesis.\",\n      \"method\": \"Primary cell isolation from Arid5b-/- mice, microarray, RT-PCR, Western blot, ELISA (PGI2), Boyden chamber migration assay, iloprost rescue experiment\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (microarray, RT-PCR, ELISA, functional rescue) in KO cells establishing pathway position; single lab\",\n      \"pmids\": [\"29196500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Arid5b knockout in skeletal muscle leads to increased basal glucose uptake, glycogen content, glucose oxidation, and ATP production. The mechanistic basis involves downregulation of TBC1D1 (a negative regulator of GLUT4 translocation), resulting in increased GLUT4 localization at the plasma membrane in Arid5b-/- muscle.\",\n      \"method\": \"Arid5b-/- mouse skeletal muscle analysis, glucose uptake assays, glycogen measurements, coimmunofluorescence for GLUT4/dystrophin, protein expression analysis\",\n      \"journal\": \"Biological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — KO model with multiple metabolic readouts and GLUT4 localization by immunofluorescence; single lab\",\n      \"pmids\": [\"33023658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fabp4-Cre conditional Arid5b knockout mice (adipocyte-specific) are resistant to high-fat diet-induced weight gain, with decreased lipid accumulation specifically in subcutaneous (inguinal) white adipose tissue and liver, but not in gonadal WAT. RNA-seq revealed decreased expression of inflammation-associated genes in IWAT adipocytes of FSKO mice, suggesting ARID5B regulates inflammatory signaling from specific WAT depots to the liver.\",\n      \"method\": \"Conditional Fabp4-Cre; Arid5bFLOX/FLOX mouse generation, HFD challenge, tissue weight, triglyceride measurements, CD68 staining for macrophages, RNA-seq\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with multiple phenotypic readouts and RNA-seq; single lab\",\n      \"pmids\": [\"33757861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID5B risk variants at the ALL susceptibility locus function through cis-regulatory elements. CRISPR-based enhancer screening identified six cis-regulatory elements at the ARID5B locus. The top ALL risk variant (rs7090445) lies within the strongest enhancer, which is distally tethered to the ARID5B promoter. The risk allele disrupts the MEF2C binding motif, reducing MEF2C affinity and decreasing local chromatin accessibility. MEF2C influences ARID5B expression in ALL, likely via a transcription factor complex with RUNX1.\",\n      \"method\": \"dCas9-KRAB enhancer interference screening, chromatin immunoprecipitation (ChIP), coimmunoprecipitation (MEF2C-RUNX1 complex), ATAC-seq (chromatin accessibility), targeted sequencing, UK Biobank genetic analysis\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR-based enhancer screen, ChIP, Co-IP, ATAC-seq; multiple orthogonal methods establishing the molecular mechanism of risk variant action\",\n      \"pmids\": [\"35575404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID5B-PHF2 complex promotes histone demethylation at H3K36me2 at the SORBS2 promoter, thereby activating SORBS2 transcription and suppressing epithelial-to-mesenchymal transition (EMT) and tumor generation in ovarian cancer cells.\",\n      \"method\": \"ChIP (H3K36me2 at SORBS2 promoter), ARID5B overexpression/knockdown, Co-immunoprecipitation, in vivo and in vitro functional assays for EMT\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and Co-IP with functional readout for EMT; single lab with two orthogonal methods\",\n      \"pmids\": [\"37948999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ARID5B regulates B cell development at the Pre-B cell stage: Arid5b deletion in vivo and ex vivo causes increased large and small Pre-B cell proportions with enhanced proliferation, and enhanced fatty acid uptake and oxidation at the Pre-B stage. ARID5B expression is upregulated at the Pre-B stage and maintained through later B cell development.\",\n      \"method\": \"In vivo Arid5b conditional knockout and ex vivo Arid5b inhibition; flow cytometry for B cell fractions; metabolic assays (fatty acid uptake, oxidation); gene expression analysis in mouse and human bone marrow\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO and ex vivo inhibition with multiple readouts (flow cytometry, metabolic assays); single lab\",\n      \"pmids\": [\"37483604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Arid5b overexpression in mice (Vav1-driven transgenic) causes a dramatic reduction in circulating B cells and B cell fractions in peripheral blood, bone marrow, and spleen. ARID5B overexpression leads to defects in B cell activation in vitro with hyperactivation of B-cell receptor signaling at baseline, and increases mitochondrial oxygen consumption rate in naïve and stimulated B cells.\",\n      \"method\": \"Vav1-Cre transgenic mouse overexpression, flow cytometry, in vitro B cell activation assays, mitochondrial oxygen consumption rate measurement\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo overexpression model with multiple functional readouts; single lab\",\n      \"pmids\": [\"35924577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Muscle-specific deletion of Arid5b leads to preferential utilization of fatty acids for energy generation in skeletal muscle, decreased adipose tissue weight (via increased phospho-HSL/HSL in WAT), and glucose diversion into the pentose phosphate pathway and glycolysis for lactate export. Glucose oxidation is reduced in conjunction with downregulation of the mitochondrial pyruvate carrier (MPC). This establishes ARID5B as a regulator of fuel selection in skeletal muscle that systemically influences adipose and liver metabolism.\",\n      \"method\": \"Skeletal muscle-specific Arid5b knockout (Arid5b MKO) mice, metabolic phenotyping, gene expression analysis, tissue weight measurements\",\n      \"journal\": \"Frontiers in endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with multiple metabolic readouts; single lab\",\n      \"pmids\": [\"36743919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID5B directly activates LINC01128 transcription by binding to its promoter (confirmed by ChIP). The long isoform of ARID5B is negatively regulated by TNF-α in rheumatoid arthritis synovial fibroblasts, and suppresses IL-6 production stimulated by TNF-α. siRNA knockdown and lentiviral overexpression of ARID5B isoforms confirmed the long isoform as a negative modulator of IL-6.\",\n      \"method\": \"siRNA knockdown, lentiviral overexpression, luciferase reporter assay, RNA immunoprecipitation, RNA pulldown, co-immunoprecipitation, ChIP\",\n      \"journal\": \"Clinical and translational medicine / Immunological medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP for direct promoter binding, KD and OE with functional readout; two independent papers with overlapping evidence\",\n      \"pmids\": [\"38224186\", \"38747454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARID5B assembles into a chromatin repressor complex with MIER1, C16ORF87, HDAC1, and HDAC2 in B-ALL cells. CUT&RUN mapping showed ARID5B binds active regions of the genome and tethers HDAC1/HDAC2 to distal regulatory elements and promoters. Genes actively repressed by this ARID5B complex are involved in B cell proliferation and B cell-specific signaling.\",\n      \"method\": \"Proteomics (mass spectrometry for complex identification), CUT&RUN (ARID5B, HDAC1, HDAC2 genome-wide binding), RNA-seq (transcriptomic effects)\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomics for complex identification plus CUT&RUN genomics; preprint, not yet peer-reviewed; multiple orthogonal methods\",\n      \"pmids\": [\"bio_10.1101_2025.10.17.683040\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In epileptogenesis, WDR5 enhances H3K4me3 deposition at the Arid5b promoter, driving transcriptional upregulation of ARID5B in hippocampal neurons. The upregulated ARID5B subsequently represses GABA-A receptor (GABAAR) subunit expression, impairing inhibitory synaptic transmission and facilitating epileptogenesis.\",\n      \"method\": \"ChIP-seq (H3K4me3 at Arid5b promoter), RNA-seq, WDR5 knockdown, neuron-specific WDR5 knockout, whole-cell patch-clamp recordings, video-EEG monitoring\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq, KO with electrophysiology and EEG readouts; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"41510154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ApoM upregulates Arid5b expression in hepatocytes, and Arid5b knockdown increases culture-medium prothrombin levels while decreasing cellular prothrombin levels, reversing ApoM's inhibitory effect on prothrombin secretion. This places ARID5B downstream of ApoM in regulation of hepatic prothrombin secretion, independent of S1P receptors.\",\n      \"method\": \"RNA-seq (Arid5b identification), Arid5b knockdown in HepG2 cells, ApoM overexpression/knockout mouse models, prothrombin ELISA\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — RNA-seq for target identification, single KD experiment with functional readout; single lab, limited mechanistic depth\",\n      \"pmids\": [\"40719152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Two transcriptionally distinct ARID5B isoforms (short and long) differ in an encoded BAH-like chromatin interaction domain. Both isoforms have functionally independent proximal promoters as shown by luciferase reporter assays. Increased short isoform expression is associated with decreased event-free and overall survival in B-ALL, and the isoform ratio strongly correlates with B-ALL prognostic stratification.\",\n      \"method\": \"RNA-seq splice junction analysis, luciferase reporter assays for independent promoter activity, correlation with clinical survival outcomes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase assay for promoter activity is mechanistic, but the functional consequence of isoform difference is correlative; single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"38382358\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARID5B is an AT-rich DNA-binding transcriptional co-regulator that functions primarily as a scaffold/DNA-targeting subunit for epigenetic complexes: it assembles with the H3K9me2 demethylase PHF2 (activated by PKA-mediated phosphorylation) to direct H3K9me2 removal at target promoters and activate transcription, and separately assembles with HDAC1/HDAC2/MIER1 to form a chromatin repressor complex at active regulatory elements; it also interacts with Sox9 to promote chondrogenesis, is regulated by Ikaros and MEF2C/RUNX1 at its own cis-regulatory elements, controls prostanoid biosynthesis (PGI2) and fatty acid/glucose metabolism in muscle, and suppresses IL-6 production in synovial fibroblasts, with its long and short isoforms having distinct promoters and potentially distinct chromatin-interaction functions relevant to B-ALL leukemogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARID5B is an AT-rich interaction domain (ARID) transcription factor that functions as a sequence-specific DNA-targeting subunit for chromatin-modifying complexes, coupling promoter recognition to histone demethylation and deacetylation to control cell differentiation and metabolism [#0, #2]. Its ARID domain recognizes the core AATA(C/T) motif through major- and minor-groove contacts, with two flexible interhelical loops (L1, L2) mediating phosphate-backbone and AT base-pair contacts [#2, #4]. Mechanistically, ARID5B associates with the PKA-activated H3K9me2 demethylase PHF2 and targets this complex to promoters to erase repressive methyl marks and activate transcription [#0]; this ARID5B–PHF2 module promotes chondrocyte differentiation through Sox9 target genes [#1] and activates SORBS2 to suppress epithelial-to-mesenchymal transition [#13]. In an opposing capacity, ARID5B assembles a chromatin repressor complex with MIER1, C16ORF87, HDAC1 and HDAC2, tethering deacetylase activity to active distal regulatory elements and promoters to repress B-cell proliferation and signaling genes [#18]. ARID5B is a central regulator of fuel selection and lipid storage: knockout mice show defective brown/white adipose lipid accumulation and resistance to diet-induced obesity [#5, #11], and muscle-specific loss reprograms substrate use through control of prostanoid (PGI2) biosynthesis, GLUT4/TBC1D1-dependent glucose handling, and mitochondrial pyruvate transport [#9, #10, #16]. In hematopoiesis, ARID5B governs Pre-B cell expansion and metabolism [#14, #15], and acts as a collaborating oncogenic factor by co-occupying genomic targets with the TAL1 complex and activating MYC in T-ALL [#7]. ARID5B's own expression is set by lineage transcription factors and enhancer variants, including Ikaros [#8] and a MEF2C/RUNX1-bound enhancer harboring an ALL risk allele [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the DNA recognition specificity of the ARID5B ARID domain, defining how this factor selects genomic targets.\",\n      \"evidence\": \"Binding interference, site-selection, and kinetic assays with base-analogue oligonucleotides\",\n      \"pmids\": [\"10329386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify in vivo target genes\", \"Affinity determinants do not explain promoter selectivity in chromatin context\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that protein dynamics, not just static structure, drive ARID-domain DNA binding, resolving how flexible loops engage the duplex.\",\n      \"evidence\": \"15N NMR relaxation and chemical shift perturbation mapping of the isolated ARID domain\",\n      \"pmids\": [\"11478881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No bound complex structure in this study\", \"Full-length protein dynamics not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the first organismal role for ARID5B, establishing it as essential for postnatal lipid accumulation and adiposity.\",\n      \"evidence\": \"Mrf2/Arid5b knockout mouse phenotyping with high-fat diet challenge\",\n      \"pmids\": [\"14651970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the transcriptional targets controlling lipid storage\", \"Tissue of action not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided the structural basis of ARID5B–DNA recognition, mapping which loops and helices contact AT base pairs.\",\n      \"evidence\": \"NMR structure of the ARID domain–DNA complex using paramagnetic spin-label constraints and docking\",\n      \"pmids\": [\"17407261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isolated domain only; no full-length or co-factor-bound structure\", \"Does not link recognition to transcriptional output\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed the core enzymatic mechanism by which ARID5B activates transcription—recruiting PKA-activated PHF2 to demethylate H3K9me2 at promoters.\",\n      \"evidence\": \"Co-IP, in vitro demethylase assays, ChIP, and PKA phosphorylation/mutagenesis\",\n      \"pmids\": [\"21532585\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter targeting specificity in vivo not defined\", \"Does not address ARID5B-only or repressive functions\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected the ARID5B–PHF2 demethylase module to a developmental program by showing it cooperates with Sox9 to drive chondrogenesis.\",\n      \"evidence\": \"Reciprocal Co-IP with Sox9, ChIP for H3K9me2, Arid5b-/- mouse phenotyping, and PHF2 knockdown rescue\",\n      \"pmids\": [\"24276541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID5B binding to Sox9-target promoters not mapped genome-wide\", \"Whether Sox9 recruits ARID5B or vice versa unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified ARID5B as a collaborating oncogenic transcription factor in T-ALL that partners genomically with TAL1 and activates MYC.\",\n      \"evidence\": \"ChIP-seq co-occupancy with TAL1, knockdown/overexpression, and zebrafish thymocyte tumor model\",\n      \"pmids\": [\"29326336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ARID5B uses its demethylase or repressor partners in this context unknown\", \"Mechanism of MYC activation not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked ARID5B expression control to the Ikaros tumor suppressor and confirmed its PHF2 interaction in ALL cells.\",\n      \"evidence\": \"Co-IP, CK2 inhibition, and ChIP for H3K4me3 at the ARID5B promoter\",\n      \"pmids\": [\"30420689\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Two orthogonal methods from a single lab\", \"Functional consequence of Ikaros-driven ARID5B levels not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended ARID5B function to immune-cell metabolism, showing a hypomethylation-induced short isoform drives oxidative metabolism and effector function in adaptive NK cells.\",\n      \"evidence\": \"siRNA knockdown/overexpression in human NK cells with mitochondrial, respiration, and IFN-γ readouts plus bisulfite sequencing\",\n      \"pmids\": [\"30061358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets driving the metabolic phenotype not identified\", \"Isoform-specific mechanism not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed ARID5B upstream of prostanoid biosynthesis in muscle differentiation by linking it to COX-1/PGI synthase and PGI2.\",\n      \"evidence\": \"Arid5b-/- primary muscle cells, microarray, PGI2 ELISA, and iloprost rescue of myogenesis defects\",\n      \"pmids\": [\"29196500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ARID5B directly binds Ptgs1/Ptgis promoters not shown\", \"Direct vs indirect regulation unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a glucose-handling axis whereby ARID5B restrains GLUT4 surface localization via TBC1D1 in muscle.\",\n      \"evidence\": \"Arid5b-/- muscle glucose uptake/glycogen assays and GLUT4 immunofluorescence\",\n      \"pmids\": [\"33023658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional control of TBC1D1 not demonstrated\", \"Single-lab metabolic study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed ARID5B acts in a depot-specific manner in adipocytes, controlling subcutaneous WAT/liver lipid storage and inflammatory gene programs.\",\n      \"evidence\": \"Adipocyte-specific Fabp4-Cre Arid5b knockout with HFD challenge, triglyceride, macrophage staining, and RNA-seq\",\n      \"pmids\": [\"33757861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of depot selectivity unknown\", \"Direct inflammatory-gene targets not validated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Explained how an inherited ALL risk variant acts mechanistically, by disrupting a MEF2C/RUNX1 enhancer that controls ARID5B expression.\",\n      \"evidence\": \"dCas9-KRAB enhancer screen, ChIP, MEF2C-RUNX1 Co-IP, ATAC-seq, and UK Biobank analysis\",\n      \"pmids\": [\"35575404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream leukemogenic consequence of altered ARID5B dosage not directly tested here\", \"Other enhancers' contributions unquantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Broadened the demethylase activity of ARID5B–PHF2 to H3K36me2 and tumor suppression, activating SORBS2 to block EMT in ovarian cancer.\",\n      \"evidence\": \"ChIP for H3K36me2 at SORBS2, ARID5B OE/KD, Co-IP, and EMT functional assays\",\n      \"pmids\": [\"37948999\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study with two orthogonal methods\", \"How substrate specificity switches between H3K9me2 and H3K36me2 unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established ARID5B as a regulator of Pre-B cell expansion and metabolism, with dosage controlling B-cell output bidirectionally.\",\n      \"evidence\": \"Conditional knockout and ex vivo inhibition plus Vav1-driven overexpression, flow cytometry, BCR signaling, and metabolic/OCR assays\",\n      \"pmids\": [\"37483604\", \"35924577\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in B cells not defined\", \"Link between metabolic and proliferative phenotypes mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Detailed how muscle ARID5B sets systemic fuel selection, controlling pyruvate oxidation and glucose partitioning with effects on adipose and liver.\",\n      \"evidence\": \"Skeletal-muscle-specific Arid5b knockout with metabolic phenotyping and gene expression\",\n      \"pmids\": [\"36743919\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct targets (e.g., MPC) not validated as ARID5B-bound\", \"Inter-organ signaling mediator unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined ARID5B isoform architecture, identifying short/long isoforms with distinct BAH-like chromatin domains, independent promoters, and prognostic relevance in B-ALL.\",\n      \"evidence\": \"RNA-seq splice analysis, luciferase promoter assays, and clinical survival correlation\",\n      \"pmids\": [\"38382358\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Functional consequence of the isoform difference is correlative, not mechanistic\", \"Chromatin role of the BAH-like domain not tested directly\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed an inflammatory regulatory role in which the ARID5B long isoform, suppressed by TNF-α, dampens IL-6 and directly activates LINC01128 in synovial fibroblasts.\",\n      \"evidence\": \"siRNA/lentiviral isoform manipulation, luciferase, RIP, RNA pulldown, Co-IP, and ChIP for promoter binding\",\n      \"pmids\": [\"38224186\", \"38747454\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which the long isoform suppresses IL-6 not fully defined\", \"Role of LINC01128 downstream unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified ARID5B as the DNA-targeting subunit of a MIER1/HDAC1/HDAC2 repressor complex, providing a deacetylase-based repressive mechanism distinct from its demethylase activity.\",\n      \"evidence\": \"Mass spectrometry proteomics, CUT&RUN for genome-wide binding, and RNA-seq in B-ALL cells (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.10.17.683040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not yet peer-reviewed\", \"How ARID5B switches between activating and repressive complexes unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected ARID5B to neuronal excitability, showing WDR5-driven ARID5B upregulation represses GABA-A receptor subunits to promote epileptogenesis.\",\n      \"evidence\": \"ChIP-seq for H3K4me3, RNA-seq, WDR5 knockdown/neuronal knockout, patch-clamp, and video-EEG\",\n      \"pmids\": [\"41510154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ARID5B binds GABAAR subunit promoters directly not shown\", \"Which ARID5B partner complex mediates repression here unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed ARID5B in hepatic coagulation control as a downstream effector of ApoM regulating prothrombin secretion.\",\n      \"evidence\": \"RNA-seq target identification, Arid5b knockdown in HepG2, ApoM mouse models, and prothrombin ELISA\",\n      \"pmids\": [\"40719152\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single knockdown with limited mechanistic depth\", \"Direct transcriptional targets in hepatocytes not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown what governs the switch between ARID5B's activating (PHF2 demethylase) and repressive (MIER1/HDAC) complexes, and how isoform identity and the BAH-like domain dictate which complex assembles at a given locus.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of full-length ARID5B with either partner complex\", \"Isoform-specific complex assembly not directly tested\", \"Determinants of context-dependent activation vs repression unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 3, 4, 0, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7, 1, 13, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 18, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 18, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 7, 17]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 18, 1]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 9, 10, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 12, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 9, 14]}\n    ],\n    \"complexes\": [\n      \"ARID5B-PHF2 demethylase complex\",\n      \"ARID5B-MIER1-HDAC1-HDAC2 repressor complex\"\n    ],\n    \"partners\": [\n      \"PHF2\",\n      \"SOX9\",\n      \"TAL1\",\n      \"MIER1\",\n      \"HDAC1\",\n      \"HDAC2\",\n      \"C16ORF87\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}